Acupoint Nanocomposite Hydrogel for Simulation of Acupuncture and Targeted Delivery of Triptolide Against Rheumatoid Arthritis
Abstract BackgroundAttenuating the inflammatory response and relieving pain are two therapeutical goals for rheumatoid arthritis (RA). Anti-inflammatory and analgesic drugs are often associated with many adverse effects due to nonspecific distribution. New drug delivery systems with effective targeting ability and other complementary strategies are on urgent need to be explored. To achieve this goal, an acupoint drug delivery system that can simulate acupuncture in relieving pain and targeted deliver anti-inflammatory drugs is constructed, which can co-deliver 2-chloro-N (6)-cyclopentyl adenosine (CCPA) and triptolide (TP). ResultsWe have successfully demonstrated that the nanocomposite hydrogel composed of TP-Human serum album nanoparticles (HSA NPs) and CCPA could effectively treat the RA. We found that this combination therapy can enhance analgesic effects while the mechanical pain threshold was 5.2 times compared with model group, and the thermal pain threshold was 1.4 times. Acupoint nanocomposite hydrogel could not only improve the accumulation of the designed nanomedicine in arthritic paws (13.5% higher than those in non-acupoint at 48h), but also cooperate with nanomedicine to exert synergetic improvement of inflammation and reduction of systemic toxicity. Furthermore, it can regulate inflammatory factors and restore the balance of Th17/Treg cell which provide a novel effective treatment strategy for RA.ConclusionThis novel therapeutic approach-acupoint nanocomposite hydrogel, builds a bridge between acupuncture and drugs which sheds light on the combination of traditional and modern medicine.